In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. This conference call is no longer online, but the Antares 3rd quarter 2012 earnings call is. Any you had ideas about? Specifically, Seagen has an anti-TIGIT antibody. I own Vertex so I certainly don't want Vertex overpaying for CRISPR Therapeutics. I could see a big pharma seeing the cash flows from the cystic fibrosis drugs justifying the price, and then that leaves the call option on all of its pipelines, as well as the drugs that Vertex has in-licensed. Gilead Sciences (GILD -1.00%) also has not been shy about making smaller deals. AMAG Pharmaceuticals (Market Cap $0.7bn) US specialty firm AMAG Pharmaceuticals Inc. is viewed as an acquisition target for companies established in women's health - specifically Novartis AG - due to the potential of bremelanotide in hypoactive sexual desire disorder (HSDD). All rights reserved. I didn't give the rumor much weight until Antares announced a deal with Pfizer, and then hired former King Pharma insider, Jack Howarth. One of the catalysts that could work in its favor is deal optimism. Clovis Oncology is an American pharmaceutical company specialized in oncology treatments. Alexion Pharma is no stranger to takeover rumors. If you're going to give me a quick up-front profit, I'm definitely going to take it and I'm not going to complain about it. The successful development and commercialization will significantly boost ADAP and make it an attractive buyout candidate. Is It Too Late to Buy Vertex Pharmaceuticals Stock? The Motley Fool owns shares of and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. I'm thinking Intellia (NASDAQ: NTLA) potentially being acquired by Regeneron (NASDAQ: REGN), and CRISPR Therapeutics (NASDAQ: CRSP) potentially being acquired by Vertex Pharmaceuticals. He has 7 years of experience investing and trading biotechnology focused equities with a specialty in identifying under-appreciated value in small caps. That's the downside there. Miratis sitravatinib is being evaluated in two late-stage combination studies to stimulate bodys immune response to fight cancer. However, the Company has turned down Elliott's recommendation. BioMarin remains on track to submit a Biologics License Application for Valoctocogene roxaparvovec to the FDA by the end of this year. Want to Get Richer? Many members of the management came from ALZA Corporation, which was one of the most successful mergers in the above list. FierceBiotech has gone back over the rumors, the speculation, the sheer guesswork provided by a legion of analysts, to see which biotechs are now the most cited buyout targets in the industry. Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (Calyxt), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the Merger Agreement), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. Pharma giant Pfizer recently announced that it will acquire Arena. GLOBAL MARKETS-Stocks buoyed by cheery data after BOJ damp squib, Nouriel Roubini: There's a massive disconnect between markets and the Fed, U.S. natgas price slump pushes 'widow maker' toward unusual contango, Germany must speed hydrogen plans this year - gas pipeline group OGE, Ian Bremmer: We're in a hot war with Russia. Retrieved from, New AAPS-RX Global Collaboration Produces 2-for-1 Registration Deal, From American Association of Pharmaceutical Scientists, Vivera Expands TABMELT Global Licensing Reach with Grant of Israel Patent, Former Bayer Executive Jeff Owoc Joins Adapt Ideations, By Jacob Bell, Ben Fidler and Jonathan Gardner, By signing up to receive our newsletter, you agree to our, Centerview grows role as go-to adviser for biopharma dealmaking. On the one hand, CAPLYTAs sales are growing significantly, on the other hand, the company has several product candidates with the potential to generate billions of dollars in sales in a few years. Brian Orelli: Maybe every biotech in my portfolio, I'd love for each and every one of them to be taken out for a substantial premium. . CRISPR Therapeutics CRSP is one of the leading gene-editing companies. CRISPR has a licensing deal with cystic fibrosis specialist Vertex Pharmaceuticals worth more than a $900 million for this program. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. Invest better with The Motley Fool. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Earlier, Merck acquired erstwhile Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 billion to build its rare diseases portfolio. Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc., a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus. RTTNews.com for Like the Medicines Co., Amarin also has a heart drug by the name Vascepa in its kitty. Use a + to require a term in results and - to exclude terms. On January 9, 2023, Biotech Acquisition Company (the "Company") received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a), due to the . Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. I'm thinking Intellia (NTLA -1.57%) potentially being acquired by Regeneron (REGN 0.83%), and CRISPR Therapeutics (CRSP 3.66%) potentially being acquired by Vertex Pharmaceuticals (VRTX 3.67%). ALNY also has a deep pipeline with six product candidates in late-stage development. 4 Biotechs That Could Be Potential Acquisition Targets in 2021. The reason is that their deal is for an over the counter product that Pfizer has in its inventory. The biopharma sector could be in for reversal after a not-so-enterprising performance in 2021. Aegis Sciences Corporation, a health care testing laboratory based in Nashville, Tenn., today announced its acquisition of the HealthTrackRx Toxicology line of business. 6. At the time, I was . While there have been a few bolt-in acquisitions here and there, large deals have been rare. Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. BioSpace is covering all the key announcements all week. Aesther Healthcare Acquisition Corp and Ocean Biomedical, Inc. announced that AEHA has filed with the U.S. Securities and Exchange Commission a definitive proxy statement in connection with its proposed business combination with Ocean and with respect to the special meeting of Aesthers stockholders scheduled to be held on February 3, 2023. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. Scott uses his ability to read situations, emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements, in both short and longer terms situations.. Many of today's most influential medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Humira, might not have become so without mergers and acquisitions. They are my opinions only. 12. This would be a similar strategy Voce followed with Obagi. The average deal size also shrank from the historical mean of $4.3 billion to $2.8 billion. AcelRx (ACRX). 11. Oncology and gene therapy were the subjects of acquisitions this year. Speights: Yeah. Get biopharma news like this in your inbox daily. Written by 2, I agree with you that the CRISPR gene-editing companies are probably near the top of the list of potential acquisition targets over the next few years. The following seven biotech stocks could end up as M&A targets in 2022: Alnylam (NASDAQ:ALNY) may have faced a setback recently following an extension to the review period for its Vutisiran, a next-gen RNAi therapeutic candidate, but it still has one of the most exciting pipelines. Medarex bought out GenPharm for $65M. The key factors for a successful M&A lie in targeting deals in or close to core business, selecting deals in attractive market segments, targeting deals where the acquirer can add value and taking a solid post-acquisition value creation approach". This developer of rare disease drug Soliris has been in acquisition crosshairs since 2016 - with Roche, Pfizer, Novartis and Amgen been reported as potential buyers. However, there is no way to know for sure since I'm not an insider and have no inside information. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. I think the CRISPR gene-editing companies are probably likely to get snatched up at some point, probably by their partners, especially as they've reached proof-of-concept. Now, it is three years since the PARP inhibitor has been approved. Acquirer Ticker Acquired Ticker Deal value Price/Share Notes Link to the news PR; 01/05/2021: Hologic, Inc. HOLX: Private-German co. $64M-leader in biopsy site markers: https://bwnews.pr/2L3d7lF: Considering its massive potential, Axsome Therapeutics it is likely to be ranked high on the shopping list of many large pharmaceutical companies for possible acquisition. In this Motley Fool Live video recorded on Jan. 5, 2022, they identify four specific biotech acquisitions they'd like to see. Perhaps Axsome Therapeutics (AXSM 1.32%) -- ticker there's AXSM -- might be a good fit for Biogen. After a rather bumpy start with disappointing sales numbers in 2019 and 2020, CAPLYTA net product revenues for the second quarter 2022 showed a 190% increase as compared to the same period in 2021 and a 58% increase over the first quarter 2022. Making the world smarter, happier, and richer. PwC also expects large-sized deals, valued at $50 billion or more, for diversifying into adjacent therapeutic areas. 7. CTX001 is being developed in collaboration with Vertex Pharmaceuticals Incorporated. In the wake of generic drugs eating into the sales of off-patent branded drugs, growing pressure from regulators to reduce the prices of drugs, drying pipelines, and ever-increasing R&D costs, there has been an increasing consolidation within the drug industry. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. It is focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. There's a company called Adicet Bio (ACET 0.46%), ticker there is ACET, I believe. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. I own Seagen. Team StockMatusow.com research and writers are: Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com. Shockwave Medical bolsters medical device portfolio with acquisition of Neovasc. The most recent update provided by the company suggests it may take several quarters for the issue to be resolved. I'm not sure. ATRS. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. I am not receiving compensation for it. The results of one of biotech's most polarizing clinical trials, an Alnylam Pharmaceuticals study in a rare disease known as transthyretin amyloidosis cardiomyopathy, are expected imminently. Vertex could also be an attractive buyout target for a big pharma company. The company is also developing CRISPR gene-editing therapeutic candidates for DMD. Biotech M&A With a Slow Start in 2020: More Deals to Follow? We at Biotech Investments see several catalysts that could make Intra-Cellular Therapies an interesting acquisition target. Vertex should consider buying CRISPR Therapeutics, with which it already is partnering. Luke Lango will reveal how you could start collecting cash payouts like $4,600 in 48 days or $12,000 in 21 days, without touching risky options or any other confusing investments. It is running mid-stage clinical trials of the drug, in combination with bezafibrate, in PBC, late-stage studies in non-alcoholic steatohepatitis (NASH) and a mid-stage study in biliary atresia. Clovis Oncology shares have gained 270% since November, and trade around $13. 2023 InvestorPlace Media, LLC. Then I'll throw one more out -- Vertex (VRTX 3.67%) buying CRISPR Therapeutics (CRSP 3.66%). Orelli: I think a pharma that wanted a lot of cash flow, but also wanted to boost up their pipeline, Vertex probably has more external deals than it has internal candidates. The company has a team of world-class researchers, trying to transform the company-owned CRISPR/Cas9 gene-editing platform into breakthrough human therapeutics. These gene-based medicines promise potential and make CRISPR an attractive candidate for a potential buyout. Furthermore, Antares and Pfizer entered into a collaboration in December 2011 for a yet still undisclosed product. There were a few, but not as many. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. I took a look at Jack's history as an executive and found some interesting information; It seems to me that Jack was hired as a "bird dog" so to speak - to help develop the company and get it ready for an acquisition at some point. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year. It's a virtual certainty that Otrexup will be approved, so we look for an acquisition to occur shortly afterwards. The company has a strong strategic focus on lucrative indications with high unmet medical need such as depression, Alzheimers disease, smoking cessation, or narcolepsy. Alnylam stock has a market capitalization of over $20 billion. In 2013, there were reports that Roche was eyeing BioMarin for a possible acquisition. Create your Watchlist to save your favorite quotes on Nasdaq.com. But there are some deals that Motley Fool contributors Brian Orelli and Keith Speights hope will happen. In December 2019, Intra-Cellulars first drug named CAPLYTA was approved by the FDA for the treatment of adult patients with schizophrenia. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. Often, these deals focused on cancer, rare diseases and immune system disorders areas of drug research that were seeing major victories in clinical trials and huge profits for treatments that made it to market. It remains to be seen if the takeover rumors are just wishful thinking or will turn into reality. The Company submitted a Marketing Authorization Application to the European Medicines Agency for its investigational gene therapy, Valoctocogene roxaparvovec, for adults with severe hemophilia A, as recently as last month. *Average returns of all recommendations since inception. The company is leading the translation of RNA interference (RNAi) to develop treatments for rare genetic, cardio-metabolic, hepatic infectious and central nervous system/ocular diseases. Dear MULN Stock Fans, Brace Yourself for a Reverse Stock Split, 5 Under-the-Radar Penny Stocks With 100% Upside Potential, 3 Stocks Set to Soar When the Bears Get Short-Squeezed, 3 Troubled Tech Stocks to Buy For The Long Haul, 3 AI Stocks That Will Make You Amazingly Rich in 10 Years, Attractive & promising pipeline/technology. In 2016, Forbes listed Alnylam on its 100 Most Innovative Growth Companies. Brian, what are some acquisitions that you'd like to see take place in the biopharmaceutical world in 2022. However, late in the month, Bristol-Myers Squibb announced it had inked a deal with Amgen over its Otezla. Who will buy? Analysts, on average, predict over 75% upside for Crispr shares. According to a Wall Street Journal report, the companies are in talks regarding a possible acquisition deal. The FDA decision on Pemigatinib is expected by May 30, 2020. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Gene-editing company Crispr (NASDAQ:CRSP) has long been considered as a potential M&A target owing to its promising technology platform and its longstanding partnership with Vertex Pharma (NASDAQ:VRTX). Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. He utilizes a combination of technical analysis, deep scientific research, and macro views to generate alpha for the team. Trading stocks is risky -- always be sure to know and understand your risk tolerance. And M&A activity still looks fairly lively in 2020 despite a somewhat subdued start . The Motley Fool has a disclosure policy. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. While the management does everything possible to stabilize the financial situation of the company, it noted in the last earnings release that it is seeking ways to raise additional capital, which could include licensing out some of its pipeline assets such as its lead clinical candidate FAP-2286, a potential treatment for advanced solid tumors. Do Not Sell My Personal Information (CA Residents Only). It was also approved in the EU. These symbols will be available throughout the site during your session. FTX Fooled the World. I have no business relationship with any company whose stock is mentioned in this article. | Merger and acquisition activity has been rather slow in the biopharma industry so far this year . product. Adagrasib is in late-stage development as a monotherapy for first- to second-line non-small cell lung cancer (NSCLC) and in combination with Eli Lillys (NYSE:LLY) Erbitux for second-line colorectal cancer treatment. Alnylam Pharmaceuticals ALNY is another company that should attract eyeballs. A Roth Capital Partners analyst remarked in May of this year that he believes ACAD is on big pharmas' radar as an acquisition target. Are you interested in learning more about small- and mid-cap biotech stocks with exceptional growth potential and some of the hottest takeover targets of the industry? I think Adicet might be a good fit for Gilead, as it's developing off-the-shelf CAR-T therapies. No. Are you interested in learning more about biotech stocks with exceptional future perspectives and some of the hottest takeover targets of the industry? But following Gilead's decision to acquire Kite Pharma in August of that year, the rumors died down. Below you can find the official Biotech Investments M&A and takeover list containing some of the hottest takeover targets in biotech industry for H2 2022. Sold Tercica to Ipsen: Mr. King served as President and General Manager of Tercica. Keith Speights: All right, Brian. This year has seen a modest rebound after a slow start, and analysts believe a further resurgence is likely. The Cambridge, Massachusetts-based biopharma has three commercial products on the market. In case of a buyout, investors often benefit of a massive premium. The company's portfolio consists of a few commercialized products and multiple clinical and pre-clinical product candidates. To read this article on Zacks.com click here. One of the hot topics in the biopharmaceutical world are mergers & acquisitions (M&A). The Motley Fool has a disclosure policy. Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report To read this article on Zacks.com click here. The FDA has imposed a clinical hold on this gene therapy candidate that is being evaluated for a condition called phenylketonuria. Just recently, Bayer bought out Conceptus for $1.1B. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. In fact, the second quarter hit a five-year low in both the value and number of biopharma transactions. The quest behind the drive is to fill potential gaps in the pipeline. I wrote this article myself, and it expresses my own opinions. On June 24, BioMarin has received a positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) for its gene therapy ValRox to treat adult patients with severe Hemophilia A. On June 14, Alnylam announced that the FDA approved its RNAi drug AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, a rapidly progressive and fatal disease with debilitating polyneuropathy manifestations for which there are few treatment options. Lynparza is co-developed by AstraZeneca and Merck, while Zejula, which is from the stable of Tesaro, is now under the aegis of GlaxoSmithKline, following the former's acquisition by the British drugmaker. Sold Conceptus to Bayer: Mr. Chung served as the Chief Commercial Officer at Conceptus. Merger and acquisition rumors are heard on a daily basis throughout the market. All rights reserved. Enclose phrases in quotes. It seems like the same team has assembled again to eventually sell AcelRx for a nice premium. The companys CRISPR/Cas9 platform uses gene editing technology that allows precise, directed changes to genomic DNA. Please disable your ad-blocker and refresh.